SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new development or finding in product specification without further noticed.
Chemical Name: 2-(1-(Aminochloromethyl)cyclohexyl)acetic acid
Shipping Temperature: Ambient
HSN Code: 38229010
Country of Origin: India
Smiles: O=C(O)CC1(C(N)Cl)CCCCC1
Gabapentine Impurity 47 is chemically 2-(1-(Aminochloromethyl)cyclohexyl)acetic acid. Gabapentine Impurity 47 is supplied with detailed characterization data compliant with regulatory guideline. Gabapentine Impurity 47 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Gabapentin.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Application of UHPLC for determination of Gabapentin drug substance and its related impurities
Ramesha.B1 2 , K. R. Venugopala Reddy 2*, Nischith.H.M 1, Amith Kumar M.K 1, Vinitha.K.V 1 and Vidyanand Ankolekar
Journal of Pharmacy Research 2012,5(8),4437-4442
Development and validation of reversed-phase high-performance liquid chromatography method for gabapentin and its related substances in capsule dosage form and excipient compatibility studies
Afroz patan*, alekhya k, vijey aanandhi m
103Asian J Pharm Clin Res, Vol 11, Special Issue 4, 2018, 102-109
Determination of gabapentin in bulk drug and in pharmaceutical dosage form by hplc method
B. udaykumar raob, f. maqdoomb and anna pratima nikaljea
J. Chil. Chem. Soc., 54, Nº 4 (2009), págs. 424-427.
A Novel Method for Assessing Drug Degradation Product Safety Using Physiologically-Based Pharmacokinetic Models and Stochastic Risk Assessment
Hoa q. nguyen,1 stephen d. stamatis,2 lee e. kirsch1
Nguyen, Stamatis, and Kirsch, journal of pharmaceutical sciences 104:3101–3119, 2015